Cutaneous Leishmaniasis
1 million new cases globally, annually.
leaf.png
leaf.png
leaf.png

The leishmaniases are a group of diseases caused by the parasite Leishmania

 

An Orphan condition with unmet needs

$3000,000,000 annual market by 2027 (Fior Market Research 2020)

 

Picture8.jpg

WHO rare disease division coordinating global effort to treat and eradicate.

Picture9.jpg

FDA – Orphan Drug designated.

Picture11.jpg

Immigration has

migrated the parasite into

North America and Europe.

The 10 countries with the highest cases reported in 2015 are: Afghanistan, Algeria, Brazil, Colombia, Iran, Iraq, Peru, the Syrian Arab Republic, Tunisia and Yemen.

leaf.png
leaf.png
leaf.png
leaf.png
leaf.png
leaf.png

Formulation by Nextar Chemipharma, Israel

 

Excellent medical research team headed by Dr. Daniela Kamir, Phd microbiology, Yale University.

 

Successful Bio-essay’s on human macrophages, 100% success, conducted by Professor Charles Jaffe, Hebrew University at Hadassah Medical Center, Jerusalem.

 

C. Leishmaniasis has no known cure, it afflicts nearly 1 million new patients every year, mostly in the Levant and North Africa. Over 10 million persons afflicted world-wide.

 

Market Potential approximately $300,000,000 annually for new patients,  An Orphan Condition with highly unmet needs..

 

Further development includes: V. Leishmaniasis, M. Leishmaniasis, Canine Leishmaniasis and Chronic Wounds.Breakthrough Therapies